Výsledky vyhledávání

Akademický článek

Real-world evaluation of health-related quality of life in patients with diffuse large B-cell lymphoma based on a multinational survey

Autor: P. Connor Johnson, Abigail Bailey, Qiufei Ma, Neil Milloy, Jake Butcher, Isaac Sanderson, Sarah Weatherby, Rachael Meadows, Ruben G. W. Quek

Publikováno v: Frontiers in Oncology, Vol 14 (2024)

BackgroundReal-world health-related quality of life (HRQoL) data in patients with diffuse large B-cell lymphoma (DLBCL) are scarce. This study is to compare patient-reported outcomes in patients with DLBCL across therapy lines and countries.MethodsDa

Externí odkaz: https://doaj.org/article/beded96e92ab43d3a884dc7a818ad785

Zobrazit plný text záznamu

Patient-reported symptom burden and treatment satisfaction in patients with metastatic urothelial cancer (mUC) in France, Germany, Italy, Spain, and the UK (Eu5)

Autor: Jane Chang, Nuno Costa, Mairead Kearney, Caspian Kluth, Callum Bleasdale, Rachel Montgomery, Melissa Kirker, Mia Unsworth, Neil Milloy, Maria Lapuente

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0310017d9ba8ee4c72bb90d2f7324cec
https://doi.org/10.26226/m.631864567e215f5e7f3852b3

Zobrazit plný text záznamu

Real-world treatment and quality of life (QOL) in locally advanced or metastatic urothelial carcinoma (la/mUC) in Saudi Arabia, Singapore, South Korea, Taiwan, and Turkey

Autor: Li-Jen Cheng, Janet Kim, Apurba Mukherjee, Neil Milloy, Mia Unsworth, Daniel Ng

Publikováno v: Journal of Clinical Oncology. 41:462-462

462 Background: Little is known about treatment and QOL of la/mUC in Saudi Arabia, South Korea, Turkey, and Taiwan. Therefore, this study assessed patient (pt), tumor, and disease characteristics; treatment sequencing; and QOL in pts with la/mUC trea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f00ee557a253a376b33526ef8b69a73b
https://doi.org/10.1200/jco.2023.41.6_suppl.462

Zobrazit plný text záznamu

Criteria used to determine platinum eligibility and first-line (1L) treatment (tx) patterns among platinum-eligible (PE) and -ineligible (PI) patients (pts) with metastatic urothelial cancer (mUC) in France, Germany, Spain, Italy, and the United Kingdom (Eu5)

Autor: Neil Milloy, Melissa Kirker, Mia Berry, Michael Kostikas, Rachel Montgomery, Mairead Kearney, Nuno Matos Costa, Jane Chang

Publikováno v: Journal of Clinical Oncology. 40:457-457

457 Background: European Society for Medical Oncology (ESMO) guidelines recommend tx for mUC based on cisplatin and platinum eligibility. To date, most real-world analyses have not included physician-confirmed eligibility status. This study collected

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8ae2d2965b35e255962d11d653aae06c
https://doi.org/10.1200/jco.2022.40.6_suppl.457

Zobrazit plný text záznamu

Use of perioperative treatment (tx) among patients (pts) undergoing radical resection (RR) for muscle-invasive urothelial cancer (MIUC) in France, Germany, Italy, Spain, the United Kingdom, the United States, Canada, China, and Japan

Autor: Edward I Broughton, Jürgen E. Gschwend, J. Alfred Witjes, Mia Berry, Michael Kostikas, Rachel Montgomery, Annabel Lambert, Siguroli Teitsson, Neil Milloy

Publikováno v: Journal of Clinical Oncology. 40:467-467

467 Background: Cisplatin-based neoadjuvant chemotherapy (NAC) followed by RR is the standard of care in cisplatin-eligible pts with MIUC. Adjuvant chemotherapy (AC) with cisplatin-based tx may be offered to those not given NAC. The unmet need this s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::eaba7378bd327af2c5f445907cd1f84c
https://doi.org/10.1200/jco.2022.40.6_suppl.467

Zobrazit plný text záznamu

Treatment Preferences Among Patients with Diffuse Large B-Cell Lymphoma: A Survey across Western Europe and the United States of America

Autor: Patrick Connor Johnson, Ruben G.W Quek, Qiufei Ma, A. Bailey, Neil Milloy, Isaac Sanderson

Publikováno v: Blood. 138:4565-4565

Introduction: Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin's lymphoma (NHL), encompassing 30-58% of all NHL cases and approximately 60,000 cases annually in the United States of America (US) alone (Tilly et al, 2015; Zol

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3d5845093166a4cbdc82579253268e1a
https://doi.org/10.1182/blood-2021-148459

Zobrazit plný text záznamu

Real-World Health-Related Quality of Life in Patients with Diffuse Large B-Cell Lymphoma: Comparisons with Reference Populations and By Line of Therapy

Autor: Neil Milloy, Jake Butcher, A. Bailey, Ruben G.W Quek, Patrick Connor Johnson, Qiufei Ma

Publikováno v: Blood. 138:4111-4111

Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common type of aggressive non-Hodgkin's lymphoma (NHL) constituting 30-58% of all NHL (Tilly et al, 2015; Thieblemont et al, 2020). Treatment can include intensive multiagent chemotherap

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4fd8e8aea368011ecc8a632e8260e0b9
https://doi.org/10.1182/blood-2021-152798

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání